Levin Capital Strategies L.P. boosted its stake in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) by 440.0% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 54,000 shares of the company's stock after acquiring an additional 44,000 shares during the period. Levin Capital Strategies L.P. owned 0.08% of EyePoint Pharmaceuticals worth $402,000 as of its most recent SEC filing.
Several other institutional investors have also recently added to or reduced their stakes in the stock. Bank of New York Mellon Corp increased its position in EyePoint Pharmaceuticals by 22.2% in the 4th quarter. Bank of New York Mellon Corp now owns 204,260 shares of the company's stock valued at $1,522,000 after acquiring an additional 37,054 shares during the period. Rhumbline Advisers increased its position in EyePoint Pharmaceuticals by 16.1% in the 4th quarter. Rhumbline Advisers now owns 89,560 shares of the company's stock valued at $667,000 after acquiring an additional 12,443 shares during the period. Deltec Asset Management LLC acquired a new position in EyePoint Pharmaceuticals in the 4th quarter valued at about $151,000. abrdn plc acquired a new position in EyePoint Pharmaceuticals in the 4th quarter valued at about $1,719,000. Finally, China Universal Asset Management Co. Ltd. increased its position in EyePoint Pharmaceuticals by 40.6% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 14,472 shares of the company's stock worth $108,000 after purchasing an additional 4,179 shares during the period. Institutional investors and hedge funds own 99.41% of the company's stock.
Wall Street Analyst Weigh In
EYPT has been the topic of several recent analyst reports. Robert W. Baird dropped their target price on EyePoint Pharmaceuticals from $38.00 to $33.00 and set an "outperform" rating on the stock in a research report on Monday, November 11th. Chardan Capital reiterated a "buy" rating and set a $33.00 target price on shares of EyePoint Pharmaceuticals in a research report on Thursday, February 6th. HC Wainwright reiterated a "buy" rating and set a $22.00 target price on shares of EyePoint Pharmaceuticals in a research report on Thursday, December 5th. Finally, Citigroup assumed coverage on EyePoint Pharmaceuticals in a report on Tuesday, January 7th. They issued a "buy" rating and a $33.00 price target on the stock. One research analyst has rated the stock with a sell rating and nine have assigned a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $26.63.
View Our Latest Report on EyePoint Pharmaceuticals
EyePoint Pharmaceuticals Stock Performance
EYPT stock traded up $0.50 on Wednesday, reaching $6.58. The company had a trading volume of 963,029 shares, compared to its average volume of 855,415. EyePoint Pharmaceuticals, Inc. has a 1 year low of $5.54 and a 1 year high of $26.76. The company's fifty day moving average is $7.28 and its 200 day moving average is $8.48. The company has a market cap of $449.09 million, a P/E ratio of -3.29 and a beta of 1.51.
EyePoint Pharmaceuticals (NASDAQ:EYPT - Get Free Report) last posted its earnings results on Wednesday, March 5th. The company reported ($0.64) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.54) by ($0.10). EyePoint Pharmaceuticals had a negative net margin of 226.57% and a negative return on equity of 43.01%. On average, sell-side analysts predict that EyePoint Pharmaceuticals, Inc. will post -2.13 earnings per share for the current year.
EyePoint Pharmaceuticals Company Profile
(
Free Report)
EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.
Read More
Before you consider EyePoint Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and EyePoint Pharmaceuticals wasn't on the list.
While EyePoint Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
